Patents by Inventor Chris Hidemi Mizufune Takimoto

Chris Hidemi Mizufune Takimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD47 AGENT-BASED TREATMENT OF CD20-POSITIVE CANCER
    Publication number: 20240218077
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat CD20+ cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.
    Type: Application
    Filed: December 19, 2023
    Publication date: July 4, 2024
    Inventors: Mark Ping Chao, Chris Hidemi Mizufune Takimoto, Jens-Peter Volkmer
  • ANTI-CD47 AGENT-BASED OVARIAN CANCER THERAPY
    Publication number: 20240150461
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat ovarian cancer using an anti-CD47 antibody. The anti-CD47 antibody can be used alone or in combination with one or more additional agent such as chemotherapy.
    Type: Application
    Filed: September 27, 2023
    Publication date: May 9, 2024
    Inventors: Chris Hidemi Mizufune Takimoto, Mark Ping Chao, Jens-Peter Volkmer
  • COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Publication number: 20240124578
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat hematopoietic disorders using an anti-CD47 agent such as an antibody and a hypomethylating agent, such as azacitidine.
    Type: Application
    Filed: September 13, 2023
    Publication date: April 18, 2024
    Inventors: Yinuo Cao, Mark Ping Chao, Ravindra Majeti, Roy Louis Maute, Chris Hidemi Mizufune Takimoto, Kelly Tran
  • Anti-CD47 agent-based treatment of CD20-positive cancer
    Patent number: 11891450
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat CD20+ cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: February 6, 2024
    Assignee: Forty Seven, Inc.
    Inventors: Mark Ping Chao, Chris Hidemi Mizufune Takimoto, Jens-Peter Volkmer
  • Anti-CD47 agent-based ovarian cancer therapy
    Patent number: 11802153
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat ovarian cancer using an anti-CD47 antibody. The anti-CD47 antibody can be used alone or in combination with one or more additional agent such as chemotherapy.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 31, 2023
    Assignee: Forty Seven, Inc.
    Inventors: Chris Hidemi Mizufune Takimoto, Mark Ping Chao, Jens-Peter Volkmer
  • Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
    Patent number: 11795223
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat hematopoietic disorders using an anti-CD47 agent such as an antibody and a hypomethylating agent, such as azacitidine.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: October 24, 2023
    Assignee: Forty Seven, Inc.
    Inventors: Yinuo Cao, Mark Ping Chao, Ravindra Majeti, Roy Louis Maute, Chris Hidemi Mizufune Takimoto, Kelly Tran
  • ANTI-CD47 BASED TREATMENT OF BLOOD CANCER
    Publication number: 20210147568
    Abstract: Methods, kits, and compositions are provided herein for determining the eligibility of a subject to receive an anti-CD47 treatment based on a presence or absence of B-cells in the subject, and subsequently treating the eligible subject with the anti-CD47 treatment alone or in combination with one or more additional agent such as an anti-CD20 antibody.
    Type: Application
    Filed: October 29, 2020
    Publication date: May 20, 2021
    Inventors: Mark Ping Chao, Roy Louis Maute, Jie Huang, Chris Hidemi Mizufune Takimoto, Balaji Agoram, Irving L. Weissman
  • COMBINATION THERAPIES FOR TREATING MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
    Publication number: 20210115140
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat hematopoietic disorders using an anti-CD47 agent such as an antibody and a hypomethylating agent, such as azacitidine.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 22, 2021
    Inventors: Yinuo Cao, Mark Ping Chao, Ravindra Majeti, Roy Louis Maute, Chris Hidemi Mizufune Takimoto, Kelly Tran
  • TREATMENT OF OVARIAN CANCER WITH ANTI-CD47 AND ANTI-PD-L1
    Publication number: 20210047416
    Abstract: Methods are provided for treating individuals with ovarian cancers with an anti-CD47 antibody and an anti PD-L1 antibody.
    Type: Application
    Filed: October 18, 2018
    Publication date: February 18, 2021
    Inventors: Chris Hidemi Mizufune Takimoto, Mark Ping Chao, Jens-Peter Volkmer
  • Anti-CD47 Agent-Based Ovarian Cancer Therapy
    Publication number: 20200283520
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat ovarian cancer using an anti-CD47 antibody. The anti-CD47 antibody can be used alone or in combination with one or more additional agent such as chemotherapy.
    Type: Application
    Filed: October 18, 2018
    Publication date: September 10, 2020
    Inventors: Chris Hidemi Mizufune Takimoto, Mark Ping Chao, Jens-Peter Volkmer
  • Anti-CD47 Agent-Based Treatment of CD20-Positive Cancer
    Publication number: 20190248915
    Abstract: Methods, kits, and compositions are provided herein that can be used to treat CD20+cancer using an anti-CD47 agent such as an antibody. The anti-CD47 agent can be used alone or in combination with one or more additional agent such as an anti-CD20 antibody.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: Mark Ping Chao, Chris Hidemi Mizufune Takimoto, Jens-Peter Volkmer